MCLA-129, an anti-EGFR/cMET bispecific antibody, is under phase I clinical trial in combination with befotertinib for safety and tolerance in advanced NSCLC patients with EGFR-sensitive mutations [102]. Here, EGFR is linked to non-small cell lung carcinoma.